Atrial fibrillation | No atrial fibriallation | Chi-square/df/p or t/d.f/p | |
---|---|---|---|
Gender (male/female) | 34 (31.8%)/12 (25.5%) | 73 (68.2%)/35 (74.5%) | 0.608/1/0.44 |
BMI (kg/m2) | 25.3 ± 3.7 | 25.4 ± 3.2 | -0.176/145/0.86 |
Waist (cm) | 93.5 ± 11.7 | 91.6 ± 10.9 | 0.936/151/0.35 |
SBP (mmHg) | 143 ± 21 | 147 ± 16 | -1.169/152/0.24 |
DBP (mmHg) | 82 ± 10 | 81 ± 9 | 1.069/152/0.29 |
Concomitant disorders, n (%) | |||
Hypertension | 38 (82.6%) | 83 (76.9%) | 0.635/1/0.43 |
MI | 6 (13.0%) | 11 (10.2%) | 0.268/1/0.60 |
HF | 7 (15.2)* | 0 (0.0%) | < 0.001 (Fisher) |
Valve surgery | 3 (6.5%)* | 1 (0.9%) | 0.046 (Fisher) |
CABG/PCI | 6 (13.0%) | 8 (7.4%) | 1.240/1/0.27 |
Cerebrovascular disease | 5 (10.9%)* | 2 (1.9%) | 0.025 (Fisher) |
Medication, n (%) | |||
Warfarin | 33 (76.1%)* | 4 (3.7%) | < 0.001 (Fisher) |
Acetylic acid | 3 (6.5%) | 33 (30.6%)* | 0.001 (Fisher) |
Digitoxin | 8 (17.4)* | 0 (0%) | < 0.001 (Fisher) |
Verapamil | 10 (21.7)* | 2 (1.9) | < 0.001 (Fisher) |
Other Ca2+ blockers | 4 (8.7) | 11 (8.7) | 1.000 (Fisher) |
Beta blockers | 14 (30.4%)* | 16 (14.8%) | 5.018/1/0.03* |
ACE inhibitor | 12 (26.1%)* | 13 (12.0%) | 4.683/1/0.03* |
AT-II antagonist | 13 (28.3%)* | 13 (12.0%) | 6.051/1/0.01* |
Diuretics | 12 (26.1%)* | 5 (4.6%) | 15.125/1/<0.001* |
Statins | 18 (39.1)* | 19 (17.6) | 8.198/1/0.01* |
Laboratory parameters | |||
Total leukocyte count (109) | 6.0 ± 1.3 | 6.2 ± 1.6 | -0.52/140/0.61 |
Creatinine (μmol/l) | 84 ± 21 | 80 ± 23 | 0.93/137/0.35 |
Total cholesterol (mmol/l) | 5.2 ± 1.0* | 5.6 ± 1.1 | -2.326/140/0.02* |
Triglycerides (mmol/l) | 1.1 ± 0.8 | 1.1 ± 0.6 | 0.162/140/0.87 |
HDL-cholesterol (mmol/l) | 1.7 ± 0.6 | 1.7 ± 0.5 | 0.443/140/0.66 |
LDL-cholesterol (mmol/l) | 2.9 ± 0.9* | 3.4 ± 1.0 | -2.713/139/0.01 |